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ABSTRACT 
 
Introduction. Mutations in the leucine-rich glioma-inactivated 1 (LGI1) gene or 
epitempin cause autosomal dominant lateral temporal epilepsy (ADLTE), an epileptic 
syndrome characterized by focal seizures with prominent auditory symptoms and 
benign clinical course. Lgi1 function is not completely defined and it seems to mediate 
proteins to proteins interactions in synapses. To date, 38 LGI1 mutations have been 
described and most of them inhibit protein secretion (loss-of-function). In the present 
study we aimed to better define the clinical phenotype of ADLTE associated with LGI1 
mutations and to further investigate the pathogenic mechanisms underlying the 
syndrome. Particularly we evaluated the functional effect of some identified mutations.   
Methods.  Families were selected on the basis of an ADLTE diagnosis according to 
defined diagnostic criteria. Almost all the affected individuals were submitted to clinical 
assessment, video-electroencephalogram (EEG) monitoring and magnetic resonance 
imaging (MRI). A positron emission tomography (PET) and a psychiatric assessment 
by means of validated psychometric scales were obtained in some individuals. Genetic 
analysis included LGI1 sequencing  and multiple ligation-dependant probe amplification 
(MLPA) assay in patients without point mutations. The expression of Lgi1 mutant 
proteins was evaluated in cultured cells by a secretion assay. The interaction of 
extracellular Lgi1 mutated proteins with ADAM 22/23 receptors (a Disintegrine and 
Metallopeptidase domain family)  was investigated by means of both co-transfection 
and immunofluorescence and   co-immuno-precipitation assays.   
Results. Four families out of eight identified were included into the study. Three 
presented missense mutations and one a microdeletion. PET study demonstrated a 
mild hypermetabolism of the right temporal lobe in patients compared to controls at 
SPM analysis. Psychiatric assessment provided evidence for a psychiatric diagnosis in 
most of the patients and for higher level of impulsiveness in patients compared to a 
control group.  Two mutations (R406C; T380A) were showed to not impair completely 
protein secretion. However they reduced Lgi1 binding to ADAM22/23 receptors.  
Discussion and conclusions.  We described four families with different LGI1 
mutations. In our patients we noticed a prevalence of ictal symptoms different from 
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auditory auras higher than previously reported in other series. A psychiatric comorbidity 
was also present and seems to emerge as a new aspect in some ADLTE families. As 
to genetic aspects we found a microdeletion in one family, confirming the possibility of 
copy number variations (CNVs) as causative mutations. The functional study 
demonstrated a pathogenic mechanism different from inhibition of secretion for  two 
mutations suggesting a possible role of the ADAM22/23 receptors in the pathogenesis 
of this condition. 
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1. INTRODUCTION 
 
1.1 Autosomal Dominant Lateral Temporal  Epilepsy (ADLTE) 
 
Autosomal dominant lateral temporal epilepsy (ADLTE), also known as autosomal 
dominant partial epilepsy with auditory features (ADPEAF), is a rare familial condition 
characterized by focal seizures with prominent auditory or aphasic symptoms, onset in 
adolescence or early adulthood, absence of brain structural abnormalities and overall 
benign outcome [1; 2]. The syndrome segregates with an autosomal dominant pattern 
with reduced penetrance [3]. Its prevalence is unknown but it may represent about 19% 
of genetic focal epilepsies [4]. Clinical diagnosis is based on the presence of at least 
two cases with non symptomatic focal or secondarily generalized seizures whose 
symptoms suggest a lateral temporal lobe origin. Focal seizures are characterized by 
auditory auras in about 2/3 of the cases [2]. Auditory symptoms are often described as 
simple sounds (such as humming, buzzing, ringing); less frequently as complex 
hallucinations (music, voices) or a distortion of sounds. Aphasic seizures may also 
sometimes be present in some kindred. Other less frequent auras include complex 
visual, psychic, autonomic, vertiginous and other sensory symptoms, usually in 
association with auditory phaenomena. Secondary generalized  tonic-clonic seizures 
are frequent particularly during sleep, sometimes causing elementary focal seizures be 
underestimated [2; 5; 6]. Standard MRI is normal by definition. Interictal 
electroencephalograms usually show mild lateral temporal abnormalities such as 
slow/sharp waves in about half of the patients, sometimes with left side prevalence [7; 
8]. Genetic studies have revealed mutations in the leucine-rich, glioma inactivated 
gene (LGI1) in about 30% of the families providing evidence for a genetic 
heterogeneity of this condition. Detailed analysis of families with and without LGI1 
mutations failed to demonstrate significant phenotypic differences among them [5; 6]. 
Since its first description, 39 mutated families have been reported worldwide, most of 
which with unique LGI1 mutations [9]. Very recently a new gene, reelin (RELN), has 
been associated to ADLTE in seven families without LGI1 mutations. Dazzo et al 
reported RELN heterozigous mutations in 17.5% of ADLTE families [10]. Moreover 
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linkage to chromosome 19q13.11-q13.31 has been reported in a large Brazilian family 
with ADLTE and migraine [11].  
Sporadic, non familial patients with auditory seizure have been reported and named 
IPEAF (Idiopathic Epilepsy with Auditory Features) [12]. Their clinical picture is almost 
identical to ADLTE except for their negative family history. De novo LGI1 mutations 
have been found in three sporadic cases [13; 14; 15].  
 
1.2 LGI 1/Epitempin 
The LGI1 gene is located on chromosome 10q and consists of eight exons. It is 
mainly expressed in neurons, particularly in the neocortex and limbic regions [16; 17].  
It encodes a protein of 557 aminoacids which is secreted into the extracellular 
compartment and shows no similarities with ion channels [18; 19]. The Lgi1 protein’s 
structure consists of a signal peptide and two distinct structural domains: the N terminal 
region contains four leucine-rich repeats (LRR) flanked by conserved cysteine clusters 
[20], whereas the C-terminal contains seven copies of a repeat named EPTP or 
epitempin [21], which form a beta-propeller domain [22]. Both domains have been 
showed to mediate protein to protein interactions [20; 22]. This gene and its product 
have been associated with different clinical phenotypes. It was first described in 1998 
as a putative tumor suppression gene, involved in a chromosomal rearrangement in 
the T98G malignant glioma cell line. Subsequent studies failed to confirm its role in 
oncogenesis [23; 24]. In 2002, LGI1 heterozygous mutations were identified to cause 
ADLTE in several European and American families [16; 17]. To date, a total of 38 LGI1 
mutations have been described: 35 mutations segregate in 39 affected families, 
whereas three are de novo mutations identified in IPEAF patients [13; 15; 17]. Of these 
mutations, 24 allow single aminoacid substitutions, 13 result in protein truncation due 
to frameshift deletions or insertions and to non-sense or splice-site mutations. So 
nearly all LGI1 mutations described are point mutations, either nonsynonymous or 
splice-site mutations or short indels, distributed along the gene length [25; 26], and two 
microdeletions, one spanning the first four exons, have been reported [27; 28]. The 
overall penetrance of LGI1 mutations is estimated to be around 66% [3] and the 
proportion of families with penetrance ≥ 75% was similar among missense and 
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truncation mutations [26].  All but three LGI1 mutations so far reported have been 
demonstrated to inhibit protein secretion, suggesting a loss of function effect [25; 29; 
30]. A three–dimensional in silico model of the two epitempin domains was built to 
predict possible structure/function relationship. It identifies a possible protein binding 
site in the beta propeller domain and another in the LRR domain. This functional model 
indicates that Lgi1 may mediate the interactions between proteins to different synaptic 
sites. It may also be used to predict the effects of identified mutations on protein folding 
or map them to functional surface regions [31]. 
Epitempin shows no homology with known ion channels. Its function and the 
mechanism by which it causes epilepsy remain still unclear. Three main functions have 
been proposed in the central nervous system: 
1) Inhibition of inactivation of the presynaptic voltage-gated potassium channel 
Kv1.1 [31];  
2) Potentiation of AMPA receptors-mediated synaptic transmission in the 
hippocampus through interaction with the transmembrane receptors 
ADAM22 and ADAM23 (a Disintegrine and Metallopeptidase domain family) 
[33; 34];  
3) Postnatal maturation of glutamatergic synapses, regulation of spine density, 
and dendritic prouning [35].  
Lgi1 is associated to a postsynaptic complex containing PSD95 and ADAM 22. It was 
shown to participate through this interaction in the regulation of synaptic strength at 
excitatory synapses [36]. Moreover it binds the presynaptic receptor ADAM23 to 
stimulate neurite outgrowth in vitro and dendritic arborisation in vivo and may act as a 
trans-synaptic protein connecting the pre-synaptic ADAM23 with the post-synaptic 
ADAM22 receptors [19; 37]. It has been shown that the ligand-receptor complexes 
between Lgi1 and ADAM22/23 regulate AMPA receptor-mediated synaptic 
transmission in the hippocampus, suggesting a possible molecular mechanism 
underlying ADLTE [19]. This mechanism is further supported by recent findings 
showing that Lgi1 antibodies neutralize the specific protein-protein interaction between 
Lgi1 and ADAM22/23 and this disruption reduces AMPA receptors in rat hippocampal 
neurons [34]. Remarkably, Lgi1-knockout (KO) mice present spontaneous seizures [19; 
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38; 39]. Homozygous Lgi1 KO mice have spontaneous seizures at postnatal day 10 
and die before the end of the third postnatal week, while heterozygous Lgi1 +/- mice 
exhibit increased susceptibility to sound-induced or pentylenetetrazole-induced 
seizures [19; 37].   
The pivotal role of LGI1 in epileptic disorders has been recently expanded by the 
finding of autoantibodies against Lgi1 in the sera of patients with limbic encephalitis 
(LE). LE is an autoimmune neurological disorder characterized by amnesia, confusion, 
seizures involving mostly the temporal lobes or faciobrachial dystonic motor seizures, 
and personality changes or psychosis [40; 41]. It belongs to a group of autoimmune 
synaptic encephalopathies, in which the patients develop antibodies against synaptic 
proteins, and usually is not associated with tumors [42]. Both temporal lobe and motor 
cortex seem to be sequentially involved in this disorder [43]. 
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2. AIM OF THE STUDY 
 
The present study aims to better define the clinical phenotype of ADLTE 
associated with LGI1 mutations and to further investigate the pathogenic mechanism 
underlying this epileptic condition. Therefore the aims of our research were: 
i) To identify ADLTE families among patients followed or coming to first evaluation 
for epileptic disorders at our Epilepsy Center; 
ii) To characterize phenotypically the probands and their relatives 
(electroencephalograms, MRI, PET) and to evaluate possible psychiatric 
comorbidities;   
iii) To ascertain the presence of LGI1 mutations in the ADLTE families identified; 
iv) To study the effect of the identified mutations on protein secretion and its 
interactions with ADAM 22/23 by means of in vitro functional tests. 
Genetic and functional studies have been conducted in collaboration with the 
Laboratory directed by doctor Carlo Nobile at the Institute of Neuroscience-CNR- 
Section of Padua. PET study has been conducted in collaboration with doctor Sabina 
Pappatà at the Institute of Biostructure and Bioimaging-CNR-Section of Naples.  
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3.MATERIALS AND METHODS 
 
3.1 Families 
Probands were identified among outpatients attending the Epilepsy Tertiary 
Center at the University Federico II in Naples during a five years period.  Families were 
classified as possible affected with ADLTE according to the following criteria: two or 
more affected members with a history of unprovoked seizures that in at least one of 
them are focal and characterized by auditory, aphasic, or visual symptoms highly 
suggestive of a lateral temporal onset. The absence of structural brain abnormalities 
and an autosomal pattern of inheritance were also requested. Each proband and 
almost all affected individuals were interviewed directly and examined by a skilled 
epileptologist. The clinical interview included personal and family history, as well as 
details concerning the following features: age at onset, description of ictal semeiology, 
verbatim of auras, seizure frequency and response to the treatment, possible risk 
factors. A physical and neurologic examination was also obtained.  Seizure types were 
classified according to the Partial Seizure Symptom Definitions [44]. Video-EEG 
monitoring both in wakefulness and during afternoon nap and magnetic resonance 
imaging (MRI) were obtained in almost all affected members.  
 
3.2 PET study 
Interictal brain metabolism was studied in some affected subjects by means of 
18-fluorodeoxyglucose positron emission tomography (18FDG-PET). 
FDG-PET. Subjects fasted for at least 6 hours. Before radiopharmaceutical injection, 
blood glucose was checked and was <140 mg/dL in all cases. After a few minutes 
(min) rest in a silent and obscured room, patients and controls were injected with a 
dose of 185–250 MBq of 18F fluorodeoxyglucose in resting state and eyes closed 
conditions, and remained in a dimly lit room with minimal background noise for about 
40 minutes. PET acquisition started between 45 and 60 minutes after injection and 
lasted 15 minutes. Brain images were acquired in 3-dimensional mode using a whole 
body PET/CT scanner (Discovery LS, GE Medical System) with an axial field of view of 
15.2 cm, yielding 35 slices of 4.25 mm thickness and an axial and transaxial resolution 
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(full width at half maximum [FWHM]) of 4.7 and 4.8 mm. Images were reconstructed 
with iterative reconstruction (FORE-Iterative) and corrected for attenuation using the 
CT scan. FDG-PET images were converted to Analyze format and exported for data 
analysis using a voxel-based methods. Images were spatially normalized into the 
Montreal Neurological Institute (MNI) space using the PET imaging–derived template 
and the default spatial normalization settings (affine transformation with nonlinear 
components, voxel size of 2 x2 _x2 mm) of SPM2 (Wellcome Department of Cognitive 
Neurology, London, UK; http://www.fil.ion.ucl. ac.uk/spm).  
Data analysis. Visual and statistical analyses were performed in patients with ADLTE. 
For statistical voxel-based analysis performed using SPM2, spatially normalized FDG-
PET images were smoothed with a gaussian filter of 10 mm FWHM. A single-subject 
conditions (controls, ADLTE) and covariates model of SPM2 were applied, using global 
normalization. Differences among patients and controls (n=12; age range: 35-64 years) 
were set at a threshold of p <0.001 uncorrected for peak height and p<0.05 corrected 
at cluster level. Both the hypotheses patients<controls and patients>controls were 
explored. 
 
3.3 Psychiatric assessment 
A psychiatric interview and a complete assessment by means of validated 
psychometric scales (SCID I and II, TAS-20, BDI-II, STAY-Y,BIS-11) were obtained in 
family members who gave their consent.  
Specifically trained psychiatric interviewers administered the research version of the 
Structured Clinical Interview for DSM-IV (SCID). The Structured Clinical Interviews for 
DSM-IV Axis I Disorders (SCID-I) [45] and Axis II Disorders (SCID-II) [46] are 
diagnostic semi-structured interviews used to determine both DSM-IV Axis I disorders 
(major mental disorders) and DSM-IV Axis II disorders (personality disorders). 
Structured psychiatric interviews are proven to specifically contribute to a better 
evaluation of the true prevalence of psychiatric comorbidities in temporal lobe epilepsy  
[47] and chronic epileptic patients [48]. SCID-II has been previously used in epileptic 
patients to define personality disorders [49]. The Toronto Alexithymia Scale (TAS-20) is 
a self-report 20 items commonly used to measure alexithymia [50]. It has been 
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validated in a sample from Italy [51] and it has also been used for psycho-pathological 
assessment of epileptic patients [52]. The Barratt Impulsiveness Scale (BIS-11) is a 30 
items questionnaire designed to assess the personality/behavioral construct of 
impulsiveness and divided into three subscales [53]. It has an overall score ranging 
from 30 to 120 points and its values show a normal distribution in the general 
population [54]. A validated Italian version of BIS-11 is available [55]. Moreover it was 
used to investigate the impulsive dimension among temporal lobe epileptic patients 
[56]. According to the literature, we decided to classify patients as high impulsive for 
BIS total score ≥ 72 and mild impulsive for values between 63 and 71. However no 
standardized cut-off score has been previously stated for this test. So the overall 
scores in these patients were compared to a control group matching sex and age 
distribution (psychiatric diagnosis or drug abuse in anamnesis were considered 
exclusion criteria). Data were described using means and standard deviation (SD) and 
the scores compared by t-test. The software Stata/IC 11.1 was used for the analysis. 
The Beck Depression Inventory (BDI-II) is a 21-question multiple-choice self-report 
inventory to explore main symptoms of depression and is also considered a useful 
screening tool in epileptic patients [57]. The State-Trait Anxiety Inventory (STAI) is a 
commonly used measure of trait and state anxiety and has already been used in 
temporal lobe epileptic patients to assess levels of anxiety [58; 59].  
 
3.3 Genetic analysis 
Blood samples were collected from the proband and other family members after 
signing the informed consent.  DNA was extracted by a standard phenol method and 
LGI1 exon analysis was performed by Sanger sequencing. Exons were PCR amplified 
(conditions described in Michelucci et al 2003) and sequenced by the Big Dye 
Terminator Cycle Sequencing kit (ABI PRISM, Applied Biosystems) and an ABI3730 
automated sequencer. Predictions of pathogenicity of LGI1 point mutations were made 
with Polymorphism Phenotyping 2 (PolyPhen-2; http://genetics.bwh. harvard.edu/) and 
Sorting Intolerant from Tolerant (SIFT; http://sift.jcvi.org/) programs. In probands with 
no LGI1 point mutations identified by standard methods, the number of copies of each 
LGI1 exon was analyzed by multiplex ligation-dependent analysis (MLPA). It was 
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performed using the commercial kit SALSA MLPA P408 ADLTE-LGI1 probemix (MRC-
Holland, Amsterdam, The Netherlands) and following the manu-facturer’s instructions. 
MLPA data were analyzed with the Coffalyser NET software (MRC-Holland). Ratios of 
1.0 were regarded as normal copy number, and ratios below 0.7 or above 1.3 were 
considered as deletion or duplication, respectively. Validation of the results were 
performed by real time quantitative (q)PCR. Type-it CNV SYBR Green PCR kit 
(Qiagen, Hilden, Germany) was used for relative quantification of exon copy number. 
qPCR was performed on 7500 real time PCR system (Applied Biosystems-Life 
Technologies). qPCR reactions were carried out with 10 ng of template DNA, 17.5 _M 
of each primer, 2×Type-it SYBR Green PCR Master Mix in a final reaction volume of 
25 ul. Standard curves were created by four serial dilutions from 50 ng to 1.8 ng of C1 
calibrator genomic DNA and run in triplicate.  
 
3.4 Functional studies 
 
3.4.1 Secretion assay 
Human embryonic kidney 293T (HEK 293T) cells were transfected with 
expression constructs containing the wild type and mutated LGI1 cDNAs using 
Lipofectamine 2000 (Life Technology, Grand Island, NY, USA), following the 
manufacturer instructions. Twenty-four hours after transfection, cells were washed 
twice and then refed with serum-free medium Opti-MEM (Life Technology, Grand 
Island, NY, USA).  After 16-20 hours, cells were lysed in Triton lysis buffer (25mMTris 
pH 7.4, 150 mMNaCl, 1% (vol/vol) Triton, 10% (vol/vol) Glycerol, 1mM EDTA) 
supplemented with proteases and phosphatase inhibitors. The medium was collected 
and centrifuged to pellet cell debris, and the supernatant was concentrated about 20x 
using Centricon YM30 concentrators (Merk-Millipore, Billerica, MA, USA). Cell lysates 
and concentrated media were separated on 5-15% SDS-polyacrylamide gels and then 
electroblotted onto nitrocellulose membrane. They were incubated with primary 
antibodies in tris buffered saline (TBS) containing 2% (vol/vol) shimed milk for 2 hours. 
The proteins immunostained with anti-Lgi1 antibody were detected with a horseradish 
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peroxidase-labelled secondary antibody and enhanced chemilumine-scence (ECL) 
reagent and visualized by autoradiography. 
 
3.4.2 Co-immunofluorescence assay 
The assay was performed to evaluate if the mutations R407C and T380A affect 
the interactions of extracellular Lgi1 with ADAM 22/23 receptors. COS7 cells were co-
transfected with wild-type or mutant LGI1-Flag  and HA-tagged ADAM22 or 
ADAM23cDNAs overexpressed (3 ug of total DNA). Thirty-six hours after transfection, 
cells were fixed with 4% paraformaldehyde (PFA) at room temperature for 10 min and 
blocked with PBS containing 2 mg/ml bovine serum albumin (BSA) (Sigma-Aldrich) for 
40 min. Fixed cells were stained with anti-Flag antibody, followed by Cy3-conjugated 
secondary antibody. Then, the cells were permeabilized with 0.1% Triton X-100 for 10 
min, blocked with PBS containing 2mg/ml BSA and stained with anti-HA monoclonal 
antibody, followed by Alexa-Fluor 488-conjugated secondary antibody. All the 
antibodies were diluted in 1% BSA/PBS; this was followed by washes with PBS. 
Finally, they were fixed with mounting medium containing DAPI (Vectashield; Vector 
Laboratories). Two coverslips were made for every transfection experiment, and twenty 
random fields were taken (magnification 400X). For every field the number of co-
immunostained cells (Lgi1 and ADAM 22 or ADAM 23) was counted and the 
percentage of cells with both signals on the cell surface was estimated. In total, three 
independent experiments were performed. For cell counting, slides were analyzed 
using a Leica-DM 5000B Epifluorescence microscope. Confocal images were acquired 
with a Radiance 2000 confocal microscope (BioRad). The GraphPad software program 
(http://www.graphpad.com/quickcalcs/) was used to calculate Chi-square and the two-
tailed P-value to compare the frequency of membrane-bound Lgi1 proteins between 
cells carrying the wild type Lgi1 protein and cells expressing mutated Lgi1 proteins. 
The same procedures were performed using COS7 cells co-transfected with wild-type 
LGI1-Flag and HA-tagged ADAM22 in presence of human serum (HS) of a patient 
diagnosed as affected with limbic encephalitis. The number of co-immunostained cells 
(Lgi1 and ADAM 22) was counted and the percentage of cells with both signals on the 
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cell surface was estimated in the presence respectively of 2.5%, 5%, 7.5 % and 10% 
amount of human serum. 
 
3.4.3 Co-immunoprecipitation assay 
In order to confirm the findings of the COS7 cell co-transfection and immuno-
fluorescence experiments a co-immunoprecipitation assay was performed. Lgi1-Flag 
wild-type or clinical mutants were co-transfected with HA-ADAM22 or HA-ADAM23 into 
HEK293T cells seeded on a six wells plate. Thirty-six hours after transfection, cells 
were lysed in 200 µl of lysis buffer (50 mMTris-HCl, pH 7.5, 1 mM EDTA, 1 mM sodium 
orthovanadate, 10 mM sodium β-glycerophosphate, 5 mM sodium pyropho-sphate, 
0.27 M sucrose and 1% (w/v) Tween 20 in the presence of a protease inhibitor cocktail 
(Sigma Aldrich) and incubated on ice for 20 minutes. Lysates were subsequently 
clarified by centrifugation at 14000 g for 20 minutes and 0.5 mg of total proteins in 500 
µl of volume were incubated with 0.5 µg of mouse monoclonal anti-HA antibody 
(Roche). After 2 hours of incubation at 4°C with gentle rocking, 20 µl of Protein G 
sepharose (GE Healthcare Life Sciences) were supplemented and incubated 1 hour at 
4°C. After 5 washes in washing buffer (50 mMTris/HCl, pH 7.5, 1 mM EDTA, 1 mM 
sodium orthovanadate, 10 mM sodium β-glycerophosphate, 5 mM sodium 
pyrophosphate, 0.27 M sucrose, 1% (w/v) tween 20 and 250 mMNaCl), proteins were 
eluted in 2x sample buffer (Invitrogen), separated in NuPAGE 4-12% (Life Technology) 
and electro-blotted on polyvinylidene fluoride membrane (PVDF) (Merk-Millipore). 
PVDF membranes were saturated with 10% skimmed milk in TBS supplemented with 
0.05% tween 20 and proteins detected using primary anti-HA and anti-Lgi1 antibodies 
and secondary antibodies conjugated with horseradish peroxi-dase. 
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4. RESULTS 
 
4.1 Clinical findings  
According to the previously stated diagnostic criteria, we identified eight ADLTE 
families among patients followed or coming to first evaluation for epileptic disorders at 
the Epilepsy Centre of the University of Naples Federico II during the years 2010 to 
2015. Five families presented mutations in LGI1; two were negative and one proband 
refused consent to genetic analysis. One of the mutated families was lost to follow up 
and clinical and genetic data were previously described by our group [27]. We have 
described some clinical and genetic aspects for families I and II in two papers [28; 29]. 
Finally four families were included into the study. The families’ trees are represented in 
figures from 1  to 4 A. The clinical, electrophysiological and neuroimaging data are 
summarized in table 1.  
Overall there were 12 subjects (1 deceased) with epilepsy belonging to four 
families. The age of seizure onset ranged from 9 to 65 years, with a mean of 26.4 
years. In most cases the diagnosis began in the adolescence or in the young 
childhood. Auditory auras isolated or in association were reported in 5/11 patients 
(45%). One patient reported seizures induced by external sounds (alarms, fireworks). 
Non auditory auras occurring in isolation and consisting of visual hallucinations, 
aphasia, déjà-vu and vertigo were found in 5/11 patients (45%). The auditory 
symptoms were reported as elementary or unformed sounds (whistles, buzzing) in four 
patients. Almost all the patients (9/11) presented rare generalized tonic clonic seizures 
(GTCS) during sleep; one patient presented generalized seizures alone. Clinical 
course is benign in almost all the patients and particularly in some of them who were 
seizures free after drug discontinuation (V:2 family I, II:5 family III) or never needed 
antiepileptic treatment. The EEGs showed mild abnormalities over the temporal 
regions in 5/11 patients, involving the left side in 4 of them (80%) [figure 5]. In patient 
V:2 (family I) an ictal EEG was obtained and showed focal fast rhythmic activities over 
the left anterior fronto-temporal areas during a brief episode characterized by vertigo, 
déjà-vu, fear and pallor. Brain MRI was available for all the patients and showed no 
abnormalities. Diagnosis was uncertain for the patient II:3 in family IV, since she did 
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not accept clinical evaluation. The subject III:1 in family IV presented febrile seizures in 
the childhood but he had no mutation in LGI1. Common migraine was reported by one 
patient in family IV. 
 
4.2 PET findings 
18FDG-PET scans showed mild asymmetric metabolism in the lateral temporal 
or parietal cortex (sn<dx) in 3/4 patients on a visual evaluation (figure 6 A). A voxel-
based statistical analysis performed with SPM showed a relative metabolic reduction at 
the level of the right superior frontal gyrus (Brodamann’s area (BA) 6) (24x-2y-70z) and 
left middle frontal gyrus (BA6) (-30x 8y 56z) [figure 6B]. No significant hypometabolism 
was evident in other regions including the temporal cortex. In contrast the patients 
group showed a relative increase of glucose metabolism in the right middle temporal 
gyrus (BA21) (50x-28y-10z) as compared to controls (figure 6B). 
 
4.3 Psychiatric findings  
The psychiatric interview and the administration of the previously described 
scales were completed in 7/11 patients from three different families, who gave their 
consent. Analysis of the data showed a high prevalence of psychiatric disturbances. 
All the patients but one presented at least one major psychiatric disturbance or a 
personality disorder diagnosed according to DSM IV. Borderline personality disorder 
was the most frequent finding (4/7). An eating disorder not otherwise specified was 
found in all the family III members. Moreover 5/7 patients showed high or mild 
elevation at the scale assessing impulsivity. BIS-11 scores were significantly higher in 
ADLTE patients than in healthy controls (p= 0.021, t-test) (table 2, figure 7). We also 
found high levels of anxiety (evaluated by State-Trait Anxiety Inventory) in 5/7 
patients. Depression symptoms instead were quite infrequent. Only two patients 
showed alexithymia. Detailed results of psychiatric evaluations  are summarized in 
table 3. 
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4.4 Genetic results 
Sequencing of LGI1 exons revealed mutations in the proband of families I,III and 
IV. In family I a heterozygous c.1219C>T mutation in exon 8 (figure 1B), causing an 
arginine to cysteine substitution at position 407 of the protein sequence (Arg407Cys), 
was found in the proband, in patients IV:4 and III:4 and in one asymptomatic individual 
(IV:9). The mutation was not found in other seven family members (figure 1) and in 225 
unrelated healthy controls of Italian ancestry (50 from the same geographic region of 
the study family). The Arg407 residue is evolutionarily conserved in many species; its 
substitution with cysteine is predicted to have deleterious effects (Poly Phen score 
2.031). In family III the sequencing of LGI1 revealed a novel heterozygous c.1138A>G 
mutation, giving rise to an arginine to threonine substitution at position 380 (T380A), in 
the proband and in three other affected subjects (figure 3B). The treonine 380 residue 
is highly conserved in many  species and the mutation occurs in the fourth repeat of 
the EPTP domain. It was not found in 225 unrelated healthy controls and is predicted 
as “potentially damaging” by PoliPhen2 (score 0.997). Both mutations were predicted 
to exert a dangerous effect on protein structure by an in silico model of LGI1 functional 
domains. They seem to modify a side chain of the protein Lgi1 that could be crucial to 
form a circular conserved region which has been hypothesized to be the main 
interaction interface of Lgi family proteins [32]. In family IV the sequencing of LGI1 
discovered a heterozygous three base-pair deletion, c.377-379delACA, within exon 4, 
in the proband (III:2) and in her father. No mutation was identified in her brother (III:1), 
affected with febrile seizures during the childhood. The mutation results in the in frame 
deletion of an asparagine residue, p. Asn126del, located in the second LRR.  The 
same mutation was reported in a French family and showed to inhibit protein secretion 
[60]. In family II MLPA identified a novel microdeletion spanning exon 2 in the proband 
and in his affected father (figure 2 B). The microdeletion was validated by real time 
qPCR.  Deletion of LGI1 exon 2 does not alter the translation frame and, therefore, 
results in a protein lacking the first LRR repeat.  Although it is less conserved than LRR 
repeats 2—4, the first LRR repeat of the Lgi1 protein is important for the stability and 
interaction properties of the LRR domain, and, therefore, its complete deletion likely 
results in a functionally defective protein [25; 31]. 
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4.5  Functional results 
Previous 3D modelling of the Lgi1 protein predicted that some ADLTE-causing, 
non synonymous,  mutations in the C-terminal EPTP domain have no apparent effect 
in protein folding but are crucial for proteins interactions mediated by EPTP domain 
[31]. In agreement with this hypothesis, we evaluated the effects of the identified LGI1 
mutations, R407C and T380A, both affecting residues at the C-terminal EPTP 
domains, on the secretion of Lgi1 by means of a secretion test assay. Both mutant 
proteins as well as the wild-type protein were detected in the media of transfected cells 
and, though in variable amounts, in the cell lysates (figure 8). However we consistently 
observed in several experiments a lower amount of the Lgi1 T380A mutant protein in 
the medium than in the cell lysate, suggesting that the secretion of this mutant protein 
was only partially hampered. Thus, according to this qualitative secretion assay, the 
T380A and R407C mutations do not inhibit completely secretion of the Lgi1 protein.  
To investigate whether these mutations affect the interaction of extracellular Lgi1 
protein with ADAM22/23 receptors, we overexpressed the wild type and mutant LGI1-
Flag cDNAs together with HA-fused ADAM22 or ADAM23 constructs in COS7 cells 
and anti-HA antibodies and a double-immunofluorescence analysis was carried out 
using confocal imaging. As shown in figure 9 and table 4, we observed that the wild-
type Lgi1 protein, when co-expressed with either ADAM22 or ADAM23, mostly co-
localized with either receptor on the cell surface, whereas mutant Lgi1 proteins failed to 
interact or poorly interacted with ADAM22/23 receptors. Overall, the percentage of Lgi1 
mutant proteins bound to either ADAM receptor on the cell surface (0-33%) was 
significantly lower than that of wild-type Lgi1 (76-88%). In order to demonstrate that the 
binding of the two proteins happens in the extracellular space, the percentage of Lgi1 
wild-type protein bound to ADAM22 on cell surface was also evaluated in the presence 
of different concentrations of human serum of a patient with limbic encephalitis 
containing antibodies against Lgi1. These antibodies were demonstrated to bind Lgi1 
on the cell surface [42]. As shown in table 5, the increasing of human serum caused a 
significant reduction of Lgi1 associated to ADAM22 since the serum antibodies 
competitively prevent the binding. 
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 To confirm co-immunofluorescence findings, a co-immunoprecipitation assay 
from HEK293T cells overexpressing HA-tagged ADAM22 or HA-ADAM23 and Lgi1-
Flag was performed. As shown in Fig. 8, HA-ADAM22, which is present in both 
immature (110 kDa) and mature (90 kDa) forms as previously observed, efficiently co-
precipitated wild-type Lgi1. Instead, both Lgi1 described mutations affected Lgi1-
ADAM22 interactions: the T380A mutation completely disrupted the interaction, 
whereas R407C mutation reduced the affinity for ADAM22. We also assessed the 
effect of these mutations on Lgi1-ADAM23 interaction using co-immunoprecipitation. 
The experiment showed that only wild-type Lgi1 was efficiently immunoprecipitated by 
ADAM23, consistent with the results obtained with ADAM22, while pathological Lgi1 
mutations displayed reduced affinity for ADAM23. However, the transfection efficiency 
of HA-ADAM23 in the presence of LGI1 was low.   
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5. DISCUSSION 
 
5.1 Clinical and instrumental findings 
We identified eight families diagnosed as possible affected with ADLTE 
according to the diagnostic criteria described in the methods section. These criteria are 
quite different from those usually reported in the literature, where auditory or aphasic 
auras are considered mandatory for the diagnosis [6]. We decided for less strict criteria 
based on the hypothesis that ADLTE associated to LGI1 mutations might not be limited 
to auditory auras but includes a subset of ictal symptoms probably originating from the 
temporal lateral cortex. Mutations in LGI1 were identified in five families and four were 
included into the study. Thus we found a proportion of ADLTE mutated families higher 
than reported in the literature (around 30%). This may be merely a causality or related 
to the families geographic origin. We might also suppose that the prevalence of LGI1 
mutations is underestimated if we consider families with only auditory features. Age at 
onset and clinical course are similar to those described in other series. We also 
observed some patients with very mild and underdiagnosed clinical manifestations and 
no need for antiepileptic treatment. In our families we found a higher prevalence of ictal 
symptoms different from auditory auras, such as visual or psychic. Families with aura 
features different from auditory symptoms have been described, including a kindred in 
which the majority of the patients had only visual auras [61]. So our observation 
supports the notion that, in addition to auditory symptoms, which are prominent in most 
families, other type of auras may be found in ADLTE, sometimes occurring in isolation. 
Tonic clinic generalized seizures occurred in the majority of cases as expected in 
epilepsies with lateral temporal origin [62]. In agreement with what was previously 
suggested [7; 8] we found a left predominance of the EEG abnormalities. Other ADLTE 
series did not confirm this finding. 
PET is a very sensitive technique for lateralization and general localization of the 
epileptogenic zone in pharmacoresistant epilepsy even when MRI and EEGs are not 
contributive [63; 64]. To date, only two PET studies have been reported in two patients 
from different Japanese families [65; 66]. They found a decreased glucose metabolism 
in the left temporal area in two patients who also showed a small volume of the left 
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superior temporal gyrus at 1.5 tesla MR brain imaging. An interictal SPECT in one 
patient was reported by Poza et al and showed a hypoperfusion of the left temporal 
lobe [61]. PET study was performed only in a small subgroup of patients. We found 
mild asymmetric metabolism in the lateral temporal or parietal cortex (sn<dx) at visual 
evaluation in 3/4 patients and no abnormalities in the patient who was seizure free from 
almost 10 years. A SPM voxel-based statistical analysis comparing ADLTE subjects 
and controls demonstrated a significant relative decrease of glucose metabolism in the 
left superior frontal gyrus and right middle frontal gyrus but failed to detect significant 
hypometabolism in the left temporal cortex despite the slight asymmetry observed in 
the PET-FDG images of 3 patients. The small number of patients could in part explain 
this last finding. It is interesting to note, however, that we found a significant relative 
metabolic increase in the right temporal cortex. We might argue that a very mild 
congenital dysfunction of the left temporal cortex, resulting only in very mild 
hypometabolism, might in turn induce a compensative hyperfunction of the right side as 
previously reported in mesial temporal lobe epilepsy [67]. In this respect some authors 
reported possible dysfunction of the left temporal cortex explored by long-latency 
auditory evoked potentials or neuropshycological tests specific for auditory processing 
[7; 8]. No certain clinic correlation may be proposed for the relative hypometabolism in 
the rostral premotor regions (BA6). Interestingly an involvement of motor cortex has 
recently been demonstrated in limbic encephalitis associated with anti-Lgi1 antibodies 
[43]. These regions might be implicated in motor but also in non motor mental-
operation tasks [68]. Further neuropsychological and PET-FDG studies in a larger 
number of patients are required to confirm our preliminary results. Overall the evidence 
of only mild PET alterations in our patients seems to be in agreement with the clinical 
benign course of the syndrome and do not support the hypotheses of underlying focal 
developmental abnormalities of potential epileptogenic significance. Tessa et al 
previously reported a cluster of increased functional anisotropy at voxel based analysis 
of diffusion tensor imaging in the left middle temporal gyrus of 8 ADLTE patients [69].  
Finally, the psychiatric evaluation demonstrated a high prevalence of psychiatric 
disturbances diagnosed by means of validated psychometric scales. Psychiatric 
comorbidities are often reported in epileptic patients [47, 49] but they have rarely been 
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found in ADLTE families. Heiman and colleagues recently evaluated depression risk in 
LGI1 mutation carriers and found that only the ones who were clinically affected with 
epilepsy showed an increased risk [70]. However depression was not a major finding in 
our patients. A high risk prevalence of hyperactive behavior has been recently reported 
in a Dutch family [71]. Psychiatric symptoms, such as explosive violent behaviors and 
panic-attack-like symptoms, have been described in a large Japanese ADLTE kindred 
carrying the LGI1 c.1418C>T (S473L) mutation [65]. We also noticed depression and 
anxiety symptoms in some members of a family we previously described [27]. These 
observations lead to the suggestion that psychiatric symptoms may be part of the 
constellation of LGI1-related clinical manifestations. Three of the families described in 
this study exhibit psychiatric symptoms, lending support to this hypothesis.  Psychiatric 
aspects look quite homogeneous and typical in the different families. Both DSM IV 
diagnosis (eating and bipolar disorders, borderline personality disorder) and high 
scores at the BIS-11 refer to the impulse control spectrum. A role of Lgi1 dysfunction in 
these disorders is also supported by the observation of psychiatric manifestations in 
limbic encephalitis. The effect of glutamatergic transmission might be a final common 
pathway [72].  
 
 
5.2 Genetic and functional studies  
Sequencing of  LGI1 exons revealed three missense mutations in families I, III 
and IV. The first two mutations were predicted to possibly impair protein to protein 
interactions by an in silico Lgi1 model [31.  The mutation identified in family IV, a three 
base-pair deletion, c.377-379delACA, and its effect on protein secretion had been 
previously described in a French family [60]. However despite the French family, in our 
patients we do not find visual symptoms and only one of them suffered from migraine 
without aura. This is against the authors’ hypothesis of a possible link between 
migraine-like episodes and ADLTE in some families. In family II MLPA identified a 
microdeletion spanning exon 2 in the proband and in his affected father. MLPA is the 
method of choice for screening large cohorts of patients for microrearrangements in 
specific genes. Two recent studies utilized this method to screen ADLTE and sporadic 
  23 
LTE patients, and no microdeletions or microduplications were found in the LGI1 gene 
[73; 74].  Although these studies were performed on limited series of patients, it was 
concluded that LGI1 microdeletions are not a frequent cause of ADLTE. In our opinion, 
the use of MLPA as a diagnostic tool to detect causative LGI1 microdeletions should be 
considered, since we found two microdeletions in two out of 12 families from our 
Epilepsy Center that were screeneed at the Biology Laboratory of Padua [27; 28]. The 
overall ratio (5:1) between point mutations and gene rearrangements observed in the 
Italian cohort of ADLTE kindreds [6, this study] is in line with that found in other genes 
for Mendelian disorders [75]. Thus, MLPA analysis of LGI1 exons should be included in 
a molecular diagnostic protocol to detect possible disease-causing copy number 
variations in ADLTE families without sequence-based mutations. As to the functional 
study we have shown that the two identified mutations, R407C and T380A, affecting 
amino acids of the C-terminal EPTP domain, allow secretion of the mutant protein, and 
that these mutations reduce affinity of Lgi1 for ADAM22 and ADAM23 neuronal 
receptors. Since the first demonstration in 2005 [18], inhibition of secretion has been 
considered the sole mechanism by which LGI1 mutations cause loss of function. The 
present work shows that other pathogenic mechanisms should be considered. In fact 
these mutations seem to allow the protein fold to be maintained while disrupt Lgi1 
interactions with other proteins. Such a decoupling is a strong indication for the 
functional relevance of the conserved surface residues forming a ring on the EPTP top 
surface. Indeed, it suggests the possibility that these residues are directly responsible 
for the Lgi1-ADAM22/23 interactions. The electrostatic surface between EPTP and 
ADAM22 is largely complementary, causing an attraction reinforced by steric 
complementarity. Any perturbation on the conserved EPTP top surface residues, or 
mutation of the ADAM22 D509 residue [33] would therefore weaken the interaction or 
even abolish it entirely. For mutations inhibiting secretion haploinsufficiency may also 
result from intracellular degradation of misfolded mutant proteins through protein 
quality-control mechanisms [76]. This hypothesis also provides a possible explanation 
for the variable amount of mutant proteins we observed in cell culture media. 
Particularly, the lower amount of the Lgi1-T380A protein in the medium compared to 
that seen in cell lysate might be due to a partial effect of this mutation on protein 
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folding. So a proportion of these proteins may be degraded and the other one secreted. 
Several studies have shown that the secreted Lgi1 protein binds to ADAM22 and 
ADAM23 receptors on the surface of neuronal cells and that these protein complexes 
exert various functions during neuronal maturation and synaptic transmission [33; 37]. 
Although their functions in the CNS are not clearly understood, the involvement of both 
ADAM22 and ADAM23 in epilepsy is suggested by studies of knock-out mice, showing 
that lack of expression of either of these genes results in spontaneous seizures [77]. 
Therefore, it has been suggested that the ligand-receptor complexes between Lgi1 and 
ADAM22/ADAM23 may be part of the molecular substrate underlying ADLTE [19]. So 
these results confirm the specificity of the binding of Lgi1 to ADAM22 and ADAM23, 
provide a pathogenic mechanism for LGI1 mutations different from the loss of the 
ability to be secreted, and strongly suggest a role for both ADAM22 and ADAM23 in the 
molecular mechanisms underlying ADLTE. Genetic disorders that are caused by 
defects in a ligand for a particular receptor are frequently mirrored by disorders in 
which there is a dysfunction of that receptor. However, a causative role for ADAM22 
and ADAM23 receptors in ADLTE was widely evaluated in genetic studies of families 
without LGI1 mutations. The direct sequencing of ADAM22 exons did not demonstrate 
any disease-causing mutations and linkage analysis with microsatellite markers within 
or near the ADAM23 gene failed to reveal any significant linkage peak [78; 79]. The 
absence of causative mutations in ADAM22 and ADAM23, however, does not exclude 
their involvement in the molecular pathway underlying ADLTE,  and many explanations 
are possible. ADAM22/23 genes may have important regulatory roles in CNS 
development and, therefore, a reduction of their expression levels due to inherited 
mutations could be detrimental for brain development in humans. It is also possible that 
mutations in these genes have not been detected in the limited set of ADLTE families 
tested because they occur at low frequency, a hypothesis supported by recent studies 
suggesting a relatively high genetic heterogeneity in ADLTE families free of LGI1 
mutations [6]. Finally, LGI1-associated ADLTE may reflect a partial loss of function of 
the Lgi1 ligand at both receptor proteins ADAM22 and ADAM23, whereas 
heterozygous mutations in only one of these receptors may not be sufficient to cause 
the syndrome. The importance of the ligand-receptor interaction between Lgi1 and 
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ADAM22/23 in epileptic disorders is also supported by the observations in limbic 
encephalitis. Lgi1 autoantibodies present in the patients’ sera specifically impair this 
binding [34]. Reduced binding of Lgi1 to ADAM22/23 may therefore be a pathogenic 
mechanism for both genetically inherited and acquired epilepsy disorders.  Our data 
are also partially confirmed by Yokoi et al in a recent study [30]. They identified two 
more mutations (S473L and R474Q) not impairing protein secretion among eight 
mutations still uncharacterized described in the literature. Then they examined the 
biochemical and histochemical behavior of Lgi1 in the brain tissue of mutant mice 
carrying respectively a secretion competent (S473L) and a secretion defective protein 
(E383A). They demonstrated in a tissue specific model that secretion defective 
proteins are misfolded and enter the ER-associated degradation pathway whereas 
secretion competent ones present a weaker binding to ADAM22. Binding to ADAM23 
seemed not to be compromised in disagreement with our findings.   
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6. CONCLUSIONS 
 
 ADLTE is an epileptic condition characterized by a wide genetic and phenotypic 
heterogeneity. In the first observations families were collected according to the 
presence of partial seizures with precocious auditory symptoms. So the phenotype was 
as homogenous as possible in order to enhance the possibilities of success of the 
linkage analysis studies for gene detection. The identification of mutations in the LGI1 
gene in a subset of families allowed the observation of ictal symptoms other than 
auditory auras in affected subjects. This finding is particularly evident in our families, 
where visual and aphasic auras or vertigo are more frequent than usually reported. In 
our families we also found a high prevalence of psychiatric comorbidities, particularly 
impulse control disorders, not previously described elsewhere in a systematic manner. 
This observation further widens the clinical spectrum of epilepsy associated with LGI1 
mutations. It also provide useful tools in the management of the patients, that often 
show poor compliance to antiepileptic treatments and may often relapse despite an 
overall benign condition. PET study provided possible interesting functional aspects of 
the syndrome even if only in a small subgroup of patients. Finally in this work, genetic 
and functional studies in two families provided evidence for different pathogenic 
mechanisms and new insights into Lgi1 functions. LGI1 is unique among epilepsy 
related genes in encoding a secreted protein, whose physiologic functions and role in 
the epileptogenesis are still poor understood. An essential role for Lgi1-ADAM 
receptors interactions was demonstrated since some mutations disrupting this binding 
can cause ADLTE without impairing completely the secretion. The same interaction is 
disrupted in acquired limbic encephalitis. However a clinical, neuroimaging and genetic 
study of further families is desiderable to better define some emerging aspects of this 
condition. 
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 7. FIGURES AND TABLES  
 
 
 
 
 
 
 
Figure 1.  Pedigree of the family I. Individuals carrying one mutant and one normal 
allele are denoted by M/-, whereas those with no mutations by -/-.  
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A)                                                              
 
 
       B) 
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Figure 2. A)Pedigree of the family II. B) Original sequence and MLPA tracings used to 
detect disease alleles. Mutated exon is indicated by arrows.  
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A)  
 
 
                B)  
  
 
Figure 3. A)Pedigree of the family III. Individuals carrying one mutant and one normal 
allele are denoted by M/-, whereas those with no mutations by -/-. B) Chromatogram 
used to detect the disease allele (variant allele denoted by an arrow).  
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A) 
 
B) 
 
Figure 4 A)Pedigree of the family IV. Individuals carrying one mutant and one normal 
allele are denoted by M/-, whereas those with no mutations by -/-. B)Chromatogram 
used to detect the disease allele (variant allele denoted by an arrow). 
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TABLE I. Clinical and instrumental findings in mutated families. 
 
Family 
ID 
Patient 
ID/sex/age 
(y) 
Seizure 
semeiology    
Seizure 
onset 
(y) 
Tonic-
clonic 
seizures 
(age, y) 
Interictal 
EEG 
MRI PET 
Out-
come 
AED 
LGI1 
mutation 
I  
   
V:2/M/30 
déja-vù, 
vertigo, fear 
12  yes (20)  
rare left 
temporal 
sharp 
waves  
N ND SF CBZ * R407C  
IV:4/F/55 déja-vù 30  no  N N ND SF none  R407C  
III:4/M/82 staring 65 no 
rare right 
temporal 
delta 
waves 
N ND SF none R407C 
II 
I:1/M/57 
visual (bright 
balls); 
auditory 
(whistles, 
noises that 
cover 
surrounding 
voices).  
9  yes  normal N ND SF CBZ  del exon2  
II:1/M/23 
visual 
(brightballs)  
15  yes  normal N ND SF VPA  del exon2  
III 
   
   
   
   
I:2/M/dead 
(69)  
NA  33  yes  ND  ND  ND    PB  ND  
II:5/M/51 
whistles in 
both ears, 
brief 
confusion 
20  yes (23)  N N ND SF none T380A  
II:7/F/49 
whistles in 
right ear, 
abdominal 
pain,  
Wernicke 
aphasia, loss 
of contact  
41  yes (43)  
left 
temporal 
sharp 
waves 
N 
Asymmetric
metabolism 
in lateral 
temporal 
cortex 
(sn<dx) 
monthly 
SPS and 
CPS  
LEV, 
OXC  
T380A  
III:1/M/32 
vertigo, 
buzzing in 
both ears, 
visual 
disturbance 
(blurring or 
foggy)  
26  no  
left 
temporal 
sharp 
waves 
during 
sleep  
N 
Asymmetric 
metabolism 
in parietal 
mesio-
temporal-
cortex 
(sn<dx) 
SF CBZ  T380A  
III:8/F/24 
GTCS during 
sleep 
17  yes (17)  normal N 
Asymmetric 
metabolism 
lateral 
temporal 
cortex 
(sn<dx) 
rare 
GTCS  
LEV  T380A  
  32 
IV II:1/M/58 aphasia 12 yes  (12) N N N 
seizure 
free  
CBZ  
c377-
379delACA 
 
III:2/F/22** 
auditory 
(deafness); 
aphasia  
11 yes  (11) 
Left 
temporal 
slow 
waves 
N ND 
Rare 
CPS 
CBZ 
c377-
379delACA 
       
 
   
 
 
 
EEG electroencephalogram; MRI magnetic resonance imaging; AED antiepileptic drugs;  GTCS 
generalized tonic clonic seizures; LEVLevetiracetam; PB Phenobarbital;  CBZ carbamazepine;  VPA 
valproate; SF seizure free; ND not done; N normal 
 
*The patient spontaneously stopped CBZ two years ago. No more seizures were reported. 
**The patient also complained migraine attacks. 
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Figure 5. Interictal EEG of the patient V:2 (family I), that shows isolated low amplitude 
spikes over the left fronto-temporal region. 
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Figure 6. A) Axial FDG-PET images in two ADLTE patients carrying T380A mutation, 
that show  a mild asymmetric FDG metabolism in lateral temporal cortex (sn<dx).  
 
 
 
 
 
 
 
 
II:7 
III:1 
control 
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6 B) SPM voxel-based statistical analysis performed with SPM showing a relative 
metabolic reduction at the level of the right superior frontal gyrus and left middle frontal 
gyrus (BA6) (B left, middle) and a relative metabolic increase in the right middle 
temporal gyrus (BA21) (B right). 
 
 
 
 
 
 
 
 
 
R L 
R 
L 
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Table 2. Summary of the demographic characteristics and BIS-11 scores in 
ADLTE patients and healthy controls 
  
Characteristics 
ADLTE 
(n=7) 
Healthy 
controls (n=7) 
Significance of 
difference (test) 
Age in years, median(IQR) 32 (22-58) 34 (21-60) / 
Gender, number of females 
(%) 
3 (43) 3 (43) / 
BIS-11,mean (SD) 70 (9.4) 56.4 (9.7) P<0.021 (t-test) 
 
 
 
 
Figure 7. Graph box showing BIS-11 score in the two groups. 
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Table 3. Psychiatric assessment  
 
Family  
Patient 
ID/sex/age 
(y) 
Psychiatric assessment 
SCID I SCID II TAS-20 BIS-11 BDI-II STAI-Y 
I  
V:2/M/30 BD-NOS 
borderline 
personality 
disorder 
normal 
high 
impulsivity 
euthymia normal 
IV:4/F/55 
major 
depressive 
episode; 
agoraphobia 
without panic 
disorder 
normal alexythymia normal 
depressive 
state 
mild 
anxiety 
II 
II:7/F/49 
ED-NOS; 
panic attack 
disorder; 
dysthymic 
disorder 
borderline 
personality 
disorder 
normal 
high 
impulsivity 
depressive 
state 
high 
anxiety 
III:1/M/32 ED-NOS normal alexythymia 
Mild  
impulsivity 
euthymia 
mild 
anxiety 
III:8/F/24 ED-NOS 
borderline 
personality 
disorder 
normal 
high 
impulsivity 
euthymia 
mild 
anxiety 
IV 
II:1/M/58 normal normal normal normal euthymia normal 
III:2/F/22 
depressive 
disorder 
borderline 
personality 
disorder 
normal 
mild 
impulsivity 
depressive 
state 
mild 
anxiety 
 
 
SCID-I = Structured Clinical Interview for DSM-IV Axis I Disorders disorders; SCID-II= Structured Clinical 
Interview for DSM-IV Axis II disorders; TAS-20=Toronto Alexithymia Scale; BIS-11= Barratt 
Impulsiveness Scale 11; BDI-II= Beck Depression Inventory II; STAI-Y= State-Trait Anxiety Inventory 
Form Y; ED-NOS= Eating disorder not otherwise specified; BD-NOS= Bipolar Disorder not otherwise 
specified. 
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Figure 8. Western blot analysis of transfected HEK293 cells. Cell lysates (L) and 
concentrated (20x) media (M) of HEK293 cells transfected with LGI1 wild type, LGI1 
1138A>G (p.T380A), LGI1 1219 C>T (R407C) expression constructs or empty vector 
were analyzed by western blot using an anti-LGI1 antibody (the image is shown with 
the permission of Dr. Nobile). 
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A)  
 
B)   
 
Figure 9 Interaction between secreted Lgi1 and ADAM22 (A) or ADAM23 (B) on the 
cell surface. COS7 cells were transiently co-transfected with wild-type or mutated 
LGI1-Flag and HA-tagged ADAM22 or ADAM23 expression constructs. Thirty-six hours 
after transfection, the Lgi1 proteins were labelled with anti-Flag antibody (red), then 
cells were permeabilized, and ADAM proteins were stained with anti-Ha antibody 
(green). Each panel displays representative confocal microscopy images, where wild-
type Lgi1 co-localized with ADAM receptors on the cell surface, whereas mutant Lgi1 
proteins failed to interact with ADAM receptors. Scale bars, 10 μm (the images are 
shown with the permission of Dr. Nobile). 
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Table 4.  Percentage of Lgi1 (wild-type or mutated) proteins bound to either 
ADAM receptor on cell surface 
 
ADAM22 Total cells Positive Negative 
    
WT 105  87 (83%) 28 (17%) 
c.1138A>G (T380A) 81 0 (0%) 81 (100%) 
c.1219C>T (R407C) 90 32 (35%) 58 (65%) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Percentage of Lgi1 wild-type protein bound to ADAM22 on cell surface 
in the presence of different concentrations of human serum containing limbic 
encephalitis antibodies against Lgi1. 
 
  % Human Serum 
Lgi1 WT 
+ 
ADAM22 
 0 2,5 5 10 
 
Total Cells 
 
115 273 254 236 
 
Membrane-
bound 
Lgi1 
87  102  93  47 
 
Not 
membrane-
bound 
Lgi1 
28 171 161 189 
 
 
 
ADAM23 Total cells  Positive  Negative  
WT  107 94 (88%) 13 (12%) 
c.1138A>G 
(T380A) 
78 0 (0%)  78 (100%) 
c.1219C>T 
(R407C) 
72 21 (29%) 51 (71%) 
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Figure 10. Wild-type or mutated Lgi 1 co-immunoprecipitated with ADAM22. The 
interaction between LGI1 and ADAM22 is affected by T380A and R407C mutations. 
FLAG-fused wt or mutated Lgi1 proteins were immunoprecipitated from equal amounts 
of HEK293T cells. Immunoprecipitates were blotted with either anti-HA (ADAM22) 
antibody or with anti-LGI1 antibody (these images are shown with the permission of Dr. 
Nobile). 
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